Oxford BioMedica PLC (OXBDF)

[marcusl2]

Oxford Biomedica has the ability to deliver the next blockbuster, how to deliver virus to T-cells in the patient directly without the need for isolating, transforming and amplifying the cells ex-vivo.

the interests of Vulpes investors and indeed all shareholders, will be protected against the threat of either unwise dilution or indeed, the threat of a takeover approach at an unreasonably low valuation. Given OXB’s unmatched gene therapy and lentivector expertise and it’s very strong patent protected IP for gene therapy manufacturing, we see OXB has a very attractive target for acquisition in a world with a growing shortage of biologics manufacturing.



HTTP://www.vulpesinvest.com/wp-content/uploads/2017/07/VLSF%20Special%20Report_Oxford%20BioMedica%20_July_2017.pdf